生物相似藥合約製造市場－全球產業規模、佔有率、趨勢、機會和預測（按產品、技術、應用、地區和競爭細分，2020-2030 年）

2024年，全球生物相似藥合約製造市場規模達93.7億美元，預計2030年將達235.4億美元，預測期內複合年成長率為16.59%。受各種慢性疾病日益流行的推動，全球生物相似藥合約製造市場正在經歷顯著成長。此外，價格低廉、治療費用可負擔的癌症生物學名藥供應日益豐富，加之全球範圍內成本效益型醫療保健體系的日益普及，這些因素共同推動了生物學名藥合約製造的需求。此外，全球老齡人口不斷成長，易患各種慢性疾病，預計也將進一步增加對生物相似藥合約製造的需求。

關鍵市場促進因素

生物製劑專利到期，促進生物相似藥發展

主要市場挑戰

生物相似藥製造的複雜性和成本高

主要市場趨勢

一次性生物加工技術在生物相似藥製造的興起

目錄

第1章：服務概述

• 市場定義
• 市場範圍
  • 覆蓋市場
  • 考慮學習的年限
  • 主要市場區隔

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球生物相似藥合約製造市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 副產物（重組非糖基化蛋白、重組糖基化蛋白）
  • 依技術分類（哺乳動物、非哺乳動物）
  • 依應用（腫瘤學、血液疾病、生長激素缺乏症、慢性及自體免疫疾病、類風濕性關節炎、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖
  • 按產品
  • 依技術
  • 按應用
  • 按地區

第6章：北美生物相似藥合約製造市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲生物相似藥合約製造市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太生物相似藥合約製造市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美洲生物相似藥合約製造市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東和非洲生物相似藥合約製造市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 合併與收購（如有）
• 產品發布（如有）
• 最新動態

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品/服務的威脅

第 14 章：競爭格局

• Catalent, Inc.
• Boehringer Ingelheim GmbH
• Alcami Corporation, Inc.
• Almac Group
• Lonza Group AG
• Biocon Limited
• Avid Bioservice, Inc.
• Rentschler Biopharma SE
• Fujifilm Kyowa Kirin Biologics Co., Ltd.

第 14 章：10 藥明生物技術有限公司

第 15 章：策略建議

第16章調查會社について,免責事項

Global Biosimilar Contract Manufacturing Market was valued at USD 9.37 billion in 2024 and is expected to reach USD 23.54 billion by 2030 with a CAGR of 16.59% during the forecast period. The global market for Biosimilar Contract Manufacturing is experiencing significant growth, driven by the growing prevalence of various chronic diseases. Additionally, increasing availability of cancer biosimilars with lowered prices and affordable treatment, along with the growing adoption of cost-effective healthcare systems across the globe, have increased the demand for biosimilar contract manufacturing. Additionally, the growing geriatric population across the globe, susceptible to different kinds of chronic diseases, is further expected to increase the demand for biosimilar contract manufacturing.

Key Market Drivers

Patent Expiry of Biologics Encouraging Biosimilar Development

The expiration of patents on many blockbusters biologic drugs has created a significant opportunity for biosimilar development, directly driving the demand for contract manufacturing organizations (CMOs) that specialize in biosimilar production. Biologics such as trastuzumab, bevacizumab, and adalimumab have either lost or are nearing the expiration of their exclusivity periods in multiple regions including the U.S., Europe, and parts of Asia. This opens the door for biosimilar manufacturers to introduce more cost-effective alternatives.

CMOs play a pivotal role in facilitating this transition by providing the infrastructure, expertise, and regulatory guidance required to bring these complex products to market efficiently. According to the U.S. Food and Drug Administration (FDA), as of 2024, over 40 biosimilars have been approved in the United States, a marked increase compared to just 11 approvals five years earlier. The European Medicines Agency (EMA) also reports steady growth in biosimilar approvals since its first authorization in 2006, reflecting a regulatory climate conducive to biosimilar uptake. The challenge of producing biologics-due to their complexity, the need for sterile environments, and sophisticated analytical testing-makes contract manufacturing a strategic choice for many biosimilar developers. Rather than investing in costly facilities and process development, pharmaceutical companies are increasingly outsourcing CMOs that already possess these capabilities, thus speeding up time-to-market and reducing capital expenditure.

Key Market Challenges

High Complexity and Cost of Biosimilar Manufacturing

Despite their economic appeal, biosimilars are biologically complex molecules that require sophisticated manufacturing infrastructure, highly skilled personnel, and rigorous quality control systems. Developing biosimilars involves extensive comparative analytical studies and process validation steps to ensure therapeutic equivalence to the original biologic, which significantly increases development time and cost. Even with outsourcing to CMOs, the cost of manufacturing biosimilars can be prohibitively high, particularly for smaller biotech firms or those targeting niche therapeutic areas. Governments such as the U.S. FDA and EMA require a comprehensive dossier of quality, safety, and efficacy data before approving a biosimilar, further increasing regulatory and financial burdens.

Moreover, CMOs must make substantial upfront investments in specialized bioreactors, cell culture facilities, and cleanroom environments to accommodate biosimilar projects. These capital-intensive requirements limit the number of CMOs equipped to handle large-scale biosimilar contracts, creating a bottleneck in supply and potentially slowing market growth.

Key Market Trends

Rise of Single-Use Bioprocessing Technologies in Biosimilar Manufacturing

One of the most prominent trends reshaping the biosimilar contract manufacturing landscape is the widespread adoption of single-use bioprocessing technologies. Single-use systems-comprising disposable bioreactors, mixing systems, and filtration units-offer significant advantages over traditional stainless-steel equipment, including reduced contamination risk, lower cleaning validation costs, and faster turnaround times between batches.

These benefits are particularly relevant in the biosimilar space, where cost efficiency and speed to market are critical. CMOs are increasingly incorporating single-use technologies to enhance their operational flexibility and meet the unique production needs of multiple clients simultaneously. According to the U.S. Department of Commerce, biopharmaceutical manufacturers who adopt single-use systems report a 30-50% reduction in production costs, making this approach especially attractive for biosimilar developers operating on tight margins.

Furthermore, these technologies support small and medium-sized batches, aligning well with the growing trend of personalized medicine and targeted biosimilars. The ability to quickly scale up or down based on demand also makes contract manufacturing more agile and responsive to fluctuating market needs.

Key Market Players

• Catalent, Inc.
• Boehringer Ingelheim GmbH
• Alcami Corporation, Inc.
• Almac Group
• Lonza Group AG
• Biocon Limited
• Avid Bioservice, Inc.
• Rentschler Biopharma SE
• Fujifilm Kyowa Kirin Biologics Co., Ltd.
• WuXi Biologics, Inc.

Report Scope:

In this report, the Global Biosimilar Contract Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biosimilar Contract Manufacturing Market, By Product:

• Recombinant Non-glycosylated Proteins
• Recombinant Glycosylated Proteins

Biosimilar Contract Manufacturing Market, By Technology:

• Mammalian
• Non-Mammalian

Biosimilar Contract Manufacturing Market, By Application:

• Oncology
• Blood Disorders
• Growth Hormonal Deficiency
• Chronic & Autoimmune Disorders
• Rheumatoid Arthritis
• Others

Biosimilar Contract Manufacturing Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Biosimilar Contract Manufacturing Market.

Available Customizations:

Global Biosimilar Contract Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Service Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biosimilar Contract Manufacturing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins)
  • 5.2.2. By Technology (Mammalian, Non-Mammalian)
  • 5.2.3. By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic & Autoimmune Disorders, Rheumatoid Arthritis, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map
  • 5.3.1. By Product
  • 5.3.2. By Technology
  • 5.3.3. By Application
  • 5.3.4. By Region

6. North America Biosimilar Contract Manufacturing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Biosimilar Contract Manufacturing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada Biosimilar Contract Manufacturing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico Biosimilar Contract Manufacturing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application

7. Europe Biosimilar Contract Manufacturing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Biosimilar Contract Manufacturing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
  • 7.3.2. Germany Biosimilar Contract Manufacturing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
  • 7.3.3. United Kingdom Biosimilar Contract Manufacturing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy Biosimilar Contract Manufacturing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Biosimilar Contract Manufacturing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application

8. Asia-Pacific Biosimilar Contract Manufacturing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Biosimilar Contract Manufacturing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
  • 8.3.2. India Biosimilar Contract Manufacturing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
  • 8.3.3. Japan Biosimilar Contract Manufacturing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
  • 8.3.4. South Korea Biosimilar Contract Manufacturing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia Biosimilar Contract Manufacturing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application

9. South America Biosimilar Contract Manufacturing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Biosimilar Contract Manufacturing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
  • 9.3.2. Argentina Biosimilar Contract Manufacturing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
  • 9.3.3. Colombia Biosimilar Contract Manufacturing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application

10. Middle East and Africa Biosimilar Contract Manufacturing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Biosimilar Contract Manufacturing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
  • 10.3.2. Saudi Arabia Biosimilar Contract Manufacturing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
  • 10.3.3. UAE Biosimilar Contract Manufacturing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products/Services

14. Competitive Landscape

• 14.1. Catalent, Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Boehringer Ingelheim GmbH
• 14.3. Alcami Corporation, Inc.
• 14.4. Almac Group
• 14.5. Lonza Group AG
• 14.6. Biocon Limited
• 14.7. Avid Bioservice, Inc.
• 14.8. Rentschler Biopharma SE
• 14.9. Fujifilm Kyowa Kirin Biologics Co., Ltd.

14.10 WuXi Biologics, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer